Literature DB >> 15884108

Expression and clinical significance of TAp73alpha, p53, PCNA and apoptosis in hepatocellular carcinoma.

Hai-Xia Qin1, Ke-Jun Nan, Guang Yang, Zhao Jing, Zhi-Ping Ruan, Chun-Li Li, Rui Xu, Hui Guo, Chen-Guang Sui, Yong-Chang Wei.   

Abstract

AIM: To study the prognostic role of TAp73alpha, p53, proliferating cell nuclear antigen (PCNA) and apoptosis in patients with hepatocellular carcinoma (HCC) after surgical tumor ablation.
METHODS: Forty-seven human resected HCC tissues and 42 adjacent non-cancerous tissues were studied with 10 normal liver tissues as control group. TAp73alpha, p53, and PCNA were detected with Elivision immunohistochemistry. Terminal deoxynucleotidyl transferase (TdT)-mediated d-UTP-biotin nick-end labeling (TUNEL) method was used to detect the apoptosis cells. All clinical and pathological materials were analyzed by SPSS10.0 statistical package.
RESULTS: TAp73alpha overexpressed in HCC tissues (36.2%) when compared with adjacent non-cancerous tissues (2.38%, P<0.005) and normal liver tissues (0, P<0.01). Mutant type p53 (mt-p53) overexpressed in HCC tissues (38.3%) when contracted with adjacent non-cancerous tissues (16.7%, P<0.05) and normal liver tissues (0, P<0.01). Proliferation index (PI) level in HCC tissues was significantly higher than that in adjacent non-cancerous tissues (30.34%+/-4.46% vs 27.88%+/-5.89%, t, P = 0.028). Apoptosis index (AI) level in HCC tissues was higher than that in adjacent non-cancerous tissues (8.62%+/-2.28% vs 7.38%+/-2.61%, t, P = 0.019). Expression of TAp73alpha was associated with lymph node metastasis and mt-p53, with r = 0.407 and 0.265, respectively. Expression of mt-p53 was associated with Edmondson's stage and AFP, with r = 0.295 and -0.357, respectively. In Kaplan-Meier univariant analysis, TAp73alpha, AFP, TNM stage, portal vein invasion, liver membrane invasion and HBsAg correlated with prognosis (log rank, P = 0.039, 0.012, 0.002, 0.000, 0.014, 0.007, respectively). Multivariant Cox regression analysis showed that TAp73alpha, AFP, TNM stage, portal vein invasion, liver membrane invasion and age were independent factors of prognosis.
CONCLUSION: These results suggest that TAp73alpha can be used as a prognostic indicator of patients with HCC undergoing surgical tumor ablation. AFP, TNM, portal vein invasion, liver membrane invasion and age also have a potency of predicting the prognosis of HCC.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15884108      PMCID: PMC4305902          DOI: 10.3748/wjg.v11.i18.2709

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  33 in total

Review 1.  E2F1 and c-Myc in cell growth and death.

Authors:  Itaru Matsumura; Hirokazu Tanaka; Yuzuru Kanakura
Journal:  Cell Cycle       Date:  2003 Jul-Aug       Impact factor: 4.534

2.  Quantitation of telomerase activity in hepatocellular carcinoma: a possible aid for a prediction of recurrent diseases in the remnant liver.

Authors:  T Suda; O Isokawa; Y Aoyagi; M Nomoto; K Tsukada; T Shimizu; Y Suzuki; A Naito; H Igarashi; M Yanagi; T Takahashi; H Asakura
Journal:  Hepatology       Date:  1998-02       Impact factor: 17.425

3.  Expression of p73 and its relation to histopathology and prognosis in hepatocellular carcinoma.

Authors:  A Tannapfel; M Wasner; K Krause; F Geissler; A Katalinic; J Hauss; J Mössner; K Engeland; C Wittekind
Journal:  J Natl Cancer Inst       Date:  1999-07-07       Impact factor: 13.506

4.  Comprehensive allelotyping of human intrahepatic cholangiocarcinoma.

Authors:  H Momoi; H Okabe; T Kamikawa; S Satoh; I Ikai; M Yamamoto; A Nakagawara; Y Shimahara; Y Yamaoka; M Fukumoto
Journal:  Clin Cancer Res       Date:  2001-09       Impact factor: 12.531

5.  Expression and prognostic roles of the G1-S modulators in hepatocellular carcinoma: p27 independently predicts the recurrence.

Authors:  Y Ito; N Matsuura; M Sakon; E Miyoshi; K Noda; T Takeda; K Umeshita; H Nagano; S Nakamori; K Dono; M Tsujimoto; M Nakahara; K Nakao; N Taniguchi; M Monden
Journal:  Hepatology       Date:  1999-07       Impact factor: 17.425

6.  Cancer statistics, 1998.

Authors:  S H Landis; T Murray; S Bolden; P A Wingo
Journal:  CA Cancer J Clin       Date:  1998 Jan-Feb       Impact factor: 508.702

7.  Role for the p53 homologue p73 in E2F-1-induced apoptosis.

Authors:  M Irwin; M C Marin; A C Phillips; R S Seelan; D I Smith; W Liu; E R Flores; K Y Tsai; T Jacks; K H Vousden; W G Kaelin
Journal:  Nature       Date:  2000-10-05       Impact factor: 49.962

8.  p53 polymorphism influences response in cancer chemotherapy via modulation of p73-dependent apoptosis.

Authors:  Daniele Bergamaschi; Milena Gasco; Louise Hiller; Alexandra Sullivan; Nelofer Syed; Giuseppe Trigiante; Isik Yulug; Marco Merlano; Gianmauro Numico; Alberto Comino; Marlene Attard; Olivier Reelfs; Barry Gusterson; Alexandra K Bell; Victoria Heath; Mahvash Tavassoli; Paul J Farrell; Paul Smith; Xin Lu; Tim Crook
Journal:  Cancer Cell       Date:  2003-04       Impact factor: 31.743

9.  p73 can suppress the proliferation of cells that express mutant p53.

Authors:  Amy C Willis; Tara Pipes; Jianhui Zhu; Xinbin Chen
Journal:  Oncogene       Date:  2003-08-21       Impact factor: 9.867

10.  Overexpression but lack of mutation and methylation of p73 in hepatocellular carcinoma.

Authors:  Huichin Pan; Shu-Ju Liao; Wen-Yung Lai; Hsi-Chi Lu; Kuang-Ming Hsiao
Journal:  Acta Oncol       Date:  2002       Impact factor: 4.089

View more
  5 in total

Review 1.  Management of hepatocellular carcinoma: Predictive value of immunohistochemical markers for postoperative survival.

Authors:  Zhao-Shan Niu; Xiao-Jun Niu; Mei Wang
Journal:  World J Hepatol       Date:  2015-01-27

2.  TP53 immunohistochemical expression is associated with the poor outcome for hepatocellular carcinoma: evidence from a meta-analysis.

Authors:  Ya-nan Ji; Qin Wang; Jun Xue
Journal:  Tumour Biol       Date:  2014-02

Review 3.  Alterations of TP53 are associated with a poor outcome for patients with hepatocellular carcinoma: evidence from a systematic review and meta-analysis.

Authors:  Jiangbo Liu; Qingyong Ma; Min Zhang; Xinshuai Wang; Dong Zhang; Wei Li; Fengfei Wang; Erxi Wu
Journal:  Eur J Cancer       Date:  2012-03-27       Impact factor: 9.162

Review 4.  The clinical utility of the proliferating cell nuclear antigen expression in patients with hepatocellular carcinoma.

Authors:  Shuangshuang Ma; Junsheng Yang; Jinpeng Li; Jinlong Song
Journal:  Tumour Biol       Date:  2015-12-17

5.  Prognostic significance of TP53 expression for patients with hepatocellular carcinoma: a meta-analysis.

Authors:  Ping Zhan; Ya-Nan Ji
Journal:  Hepatobiliary Surg Nutr       Date:  2014-02       Impact factor: 7.293

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.